Αποτελέσματα Αναζήτησης
1 Απρ 2011 · Hypo- and hyperglycemia caused by diabetes are commonly treated in hospital emergency departments. Physicians must be skilled in diagnosing and stabilizing patients with these conditions.
- The Cost of Diabetes Care—An Elephant in the Room
The increased per capita cost of care for diabetes poses an...
- The Cost of Diabetes Care—An Elephant in the Room
1 Μαΐ 2020 · This equates to £560/non-diabetes person compared with £3280/person with T1DM and £1686/person with T2DM. For people with diabetes, the net excess impact on non-elective/emergency work is £1.2 billion with additional estimated diabetes-related accident & emergency attendances at 440 000 costing the NHS £70 million/year.
19 Αυγ 2023 · Given the substantial healthcare costs and their burden on persons with diabetes, it is critical to fully understand the healthcare cost and utilization landscape for these individuals.
11 Ιουν 2020 · We classified the interventions based on their strength of evidence (strong, supportive, or uncertain) and levels of CE: cost-saving (more health benefit at a lower cost), very cost-effective (≤$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001–$50,000 per LYG or QALY), marginally cost ...
12 Απρ 2018 · The increased per capita cost of care for diabetes poses an equally urgent challenge and potential opportunity to control costs. Between 2012 and 2017, the fraction of annual per capita health care expenditures for a person with diabetes that were attributed to institutional care has decreased from 50 to 36%.
Following the TDABC approach, we calculated a cost per patient for each care pathway over a 12-month period in two steps: To calculate the capacity cost rate, the cost of all resources involved in each care pathway is determined. This cost includes personnel salaries, overheads, rent where relevant, equipment software, insurance, etc.
24 Σεπ 2020 · Early mortality in working ages cost an additional €579 per person and medications used in risk-factor treatment amounted to €418 per person. The economic burden of complications in type 2 diabetes is substantial.
